Stopped losing weight on Mounjaro — what's actually going on

The week the numbers freeze: what's happening in your body

Picture this: six or eight weeks in, you've lost a noticeable amount of weight, your clothes fit differently, and then the scales just stop. Same medicine, same general habits, same injections every Tuesday evening. Nothing feels broken, yet nothing is shifting.

This is metabolic adaptation, and it happens to almost everyone losing meaningful amounts of weight, with or without medication. As your body mass falls, it needs fewer calories to function, your basal metabolic rate quietly revises itself downward. Simultaneously, your body can increase hunger signals and reduce the energy it burns through everyday movement, sometimes without you noticing. Tirzepatide dampens appetite and slows gastric emptying, but it cannot override every adaptive mechanism the body runs.

There is also a mathematical reality. The same calorie deficit that produced fast losses at a higher starting weight produces slower losses (or none at all) at a lower weight, because the denominator has changed. A plateau at month three is not the same physiological event as stalled progress at week two. The NHS notes that weight loss on any treatment tends to be fastest in the first few months and then slows, this is expected, not a red flag. You can read more about the broader journey of losing weight on Mounjaro and what typical progress looks like over time.

Most plateaus that resolve do so within four to eight weeks. That is uncomfortable to hear, but it is the honest answer.

Why have you stopped losing weight on tirzepatide specifically, the dose question

Mounjaro's licensed titration schedule moves from the 2.5 mg starting dose up through 5, 7.5, 10, 12.5 and 15 mg, with the prescriber setting the pace. The starting dose exists primarily to help your system adjust; it is not designed to produce maximum weight reduction. If you have stopped losing weight on Mounjaro, one honest question is whether you have reached your ceiling on that dose or whether there is further room to titrate upward.

In the SURMOUNT-1 trial, published in the New England Journal of Medicine, participants on 15 mg tirzepatide achieved an average body-weight reduction of around 20–21% over 72 weeks, substantially more than participants who remained on lower doses. That gradient matters: doses are not interchangeable, and weight loss stopped on Mounjaro at mid-range doses does not mean 15 mg would produce the same result. What it does mean is that a prescriber-led dose review is worth having.

Cost context is relevant here too, and if the price of staying on treatment or increasing your dose is a concern, it is worth reading about what treatment through a regulated service actually includes, rather than assuming the figures you have seen elsewhere are the full picture.

Dose increases require evidence and a clinical assessment at nume, sorry, at our pharmacy. A prescriber reviews your case before any change is made. That review exists for your safety as well as your results.

What else can break a plateau, and what probably cannot

The clinical picture of a Mounjaro plateau is rarely about one thing. Several factors are consistently identified in weight-management research as contributors, and several popular fixes do not have much backing.

Protein intake is one of the better-supported levers. When you eat significantly less overall, as most people do on tirzepatide, hitting an adequate protein target becomes harder. Protein has a higher thermic effect than carbohydrate or fat, and preserving lean muscle mass during weight loss helps maintain metabolic rate. The British Dietetic Association and the NHS both note that protein distribution across meals, not just total calories, matters during active weight loss.

Resistance exercise is the second lever with decent evidence behind it. Cardiovascular activity burns calories in the moment; resistance training builds and maintains the muscle tissue that drives ongoing metabolic rate. Neither replaces the other.

Sleep and stress are frequently overlooked. Cortisol elevation from poor or insufficient sleep can drive appetite and impair fat loss independently of what you eat. This is not a lifestyle lecture, it is physiology, and it applies whether or not you are taking a GLP-1 or dual-agonist medicine.

What probably will not help: dramatically slashing calories further. If you are already eating very little, eating less often creates more adaptation pressure and risks micronutrient shortfalls. If you find you stop losing weight on Mounjaro despite consistent habits, this is exactly the conversation to have with your prescriber or a dietitian rather than experimenting alone. Our tirzepatide overview covers the mechanism in more detail if you want to understand how the medicine interacts with food intake physiologically.

When to speak to someone, and what that conversation looks like

If the scales have not moved for more than six to eight weeks, you are not at your highest tolerated dose, and your habits have genuinely stayed consistent, that is the moment to raise it with your prescriber rather than simply waiting longer. The same applies if you have recently changed other medicines (some interact with absorption or weight) or if you have started a new medication like methotrexate. There are specific considerations worth knowing about combining methotrexate with Mounjaro that a prescriber should factor in.

Timing of the conversation matters more than people realise. If your next repeat order falls on a bank holiday or you are away when you would normally order, a gap in treatment is a common and underappreciated cause of a temporary plateau. Consistency of dosing is part of the clinical picture, and a prescriber can help you plan around those gaps rather than just weathering them. (The 12pm Monday–Friday order cut-off for same-day dispatch means a bank holiday Monday is worth planning around.)

A longer-term stall on your highest tolerated dose, with nothing else to titrate, is a different clinical situation, one where a specialist referral or a structured review of your whole programme may be appropriate. Our clinical team, led by our clinical lead, can advise on whether your current plan is still the right one or whether something needs to change.

The NICE guidance on tirzepatide (TA1026) includes a review point: if less than 5% weight loss has occurred after six months at the highest tolerated dose, continuing the medicine is something the prescriber should formally assess. That is not a cutoff to catastrophise about, it is a structured checkpoint designed to make sure treatment is still serving you. If you are approaching that point, an honest review is more useful than quietly staying the course. Our FAQs cover common questions about reviews and repeat prescriptions if you want to understand the process before getting in touch.